Diabetes, Type 2

You have accessRestricted access
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes MellitusResults From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Robert P. Giugliano, Christopher P. Cannon, Michael A. Blazing, José C. Nicolau, Ramón Corbalán, Jindřich Špinar, Jeong-Gun Park, Jennifer A. White, Erin A. Bohula and Eugene Braunwald On behalf of the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators

Circulation. 2018;137:1571-1582, originally published December 20, 2017
https://doi.org/10.1161/CIRCULATIONAHA.117.030950

Download PDF
You have accessRestricted access
Obesity as a Disease, Not a Behavior
Penny Gordon-Larsen and Steven B. Heymsfield

Circulation. 2018;137:1543-1545, originally published April 9, 2018
https://doi.org/10.1161/CIRCULATIONAHA.118.032780

Download PDF
Open Access
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 InhibitorResults From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)
Jacob A. Udell, Zhong Yuan, Toni Rush, Nicholas M. Sicignano, Michael Galitz and Norman Rosenthal

Circulation. 2018;137:1450-1459, originally published November 13, 2017
https://doi.org/10.1161/CIRCULATIONAHA.117.031227

Download PDF
You have accessRestricted access
Reduced Mortality With Sodium-Glucose Cotransporter–2 Inhibitors in Observational StudiesAvoiding Immortal Time Bias
Samy Suissa

Circulation. 2018;137:1432-1434, originally published April 2, 2018
https://doi.org/10.1161/CIRCULATIONAHA.117.032799

Download PDF
You have accessRestricted access
Letter by Jin-shan and Xue-bin Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”
He Jin-shan and Li Xue-bin

Circulation. 2018;137:988, originally published February 26, 2018
https://doi.org/10.1161/CIRCULATIONAHA.117.031407

Download PDF
You have accessRestricted access
Response by Kosiborod et al to Letters Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”
Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu, John P. Wilding, Kamlesh Khunti, Reinhard W. Holl, Anna Norhammar, Kåre I. Birkeland, Marit Eika Jørgensen, Marcus Thuresson, Niki Arya, Johan Bodegård, Niklas Hammar and Peter Fenici On Behalf of the CVD-REAL Investigators and Study Group

Circulation. 2018;137:989-991, originally published February 26, 2018
https://doi.org/10.1161/CIRCULATIONAHA.117.031847

Download PDF
You have accessRestricted access
Letter by Koh Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”
Kwang Kon Koh

Circulation. 2018;137:984-985, originally published February 26, 2018
https://doi.org/10.1161/CIRCULATIONAHA.117.030650

Download PDF
You have accessRestricted access
CanagliflozinCui Bono?
Matthew A. Cavender and Mikhail Kosiborod

Circulation. 2018;137:335-337, originally published November 13, 2017
https://doi.org/10.1161/CIRCULATIONAHA.117.032198

Download PDF
You have accessRestricted access
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure HospitalizationThe ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Hertzel C. Gerstein, Hyejung Jung, Lars Rydén, Rafael Diaz, Richard E. Gilbert and Salim Yusuf On behalf of the ORIGIN Investigators

Circulation. 2018;137:88-90, originally published December 26, 2017
https://doi.org/10.1161/CIRCULATIONAHA.117.030924

Download PDF
You have accessRestricted access
Letter by Jin-Shan and Xue-Bin Regarding Article, “Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus”
He Jin-Shan and Li Xue-Bin

Circulation. 2017;136:1565-1566, originally published October 16, 2017
https://doi.org/10.1161/CIRCULATIONAHA.117.029960

Download PDF

Header Publisher Menu

Circulation

Diabetes, Type 2

Pages

Current Issue

Search This Journal

Related Collections

Customer Service

About Us

Our Sites

Take Action

Online Communities